IP Library Granted Patent US 8,530,619
Granted Patent B2
US 8,530,619 · App. 12/734,061 · Granted Sep 10, 2013

Identification of the hepcidin binding site on ferroportin

Inventors: Jerry Kaplan (Salt Lake City, UT); Diane M. Ward (Salt Lake City, UT); Ivana De Domenico (Salt Lake City, UT)
Assignee: University of Utah Research Foundation
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,530,619
App. No.
12/734,061
Granted
Sep 10, 2013
Kind
B2
Abstract

The invention relates to materials and procedures for the use of the hepcidin binding domain (HBD) on ferroportin. A 20 amino acid peptide of the HBD was synthesized and shown to recapitulate the characteristics and specificity of hepcidin binding to cell surface ferroportin. The affinity of hepcidin for the HBD peptide permits a rapid, sensitive assay of hepcidin in biological fluids.

Claims (8)

1. A protein-ligand conjugate suitable for use in a binding assay, which comprises: a hepcidin binding domain peptide covalently attached to a protein label or a solid support, wherein the hepcidin binding domain peptide consists of SEQ. ID. NO.: 1 and binds to hepcidin.

2. The protein-ligand conjugate of claim 1 , wherein the hepcidin binding domain peptide is attached to a solid support.

3. The protein-ligand conjugate of claim 2 , wherein the solid support is an agarose bead.

4. A protein-ligand conjugate suitable for use in a binding assay, which comprises: a hepcidin binding domain peptide covalently attached to a protein label or a solid support, wherein the hepcidin binding domain peptide comprises SEQ ID NO:1, wherein hydrophilic amino acids selected from the group consisting of arginine, aspartic acid, glutamic acid, glutamine, lysine, histidine, serine, threonine, and combinations thereof have been added at the amino and/or carboxyl terminal, and wherein the hepcidin binding domain peptide binds hepcidin.

5. The protein-ligand conjugate of claim 4 , wherein the hydrophilic amino acids are arginines.

6. The protein-ligand conjugate of claim 4 , wherein the hepcidin binding domain peptide consists of SEQ. ID. NO.:2.

7. The protein-ligand conjugate of claim 4 , wherein the hepcidin binding domain peptide is a 24, 25, 30, 35 or 40 amino acid peptide.

8. The protein-ligand conjugate of claim 4 , wherein the hepcidin binding domain peptide is a 24, 25 or 30 amino acid peptide.

Assignments (3)
CONFIRMATORY LICENSE Recorded May 28, 2015
From: UNIVERSITY OF UTAH
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 035773/0589 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 21, 2010
From: UNIVERSITY OF UTAH
To: UNIVERSITY OF UTAH RESEARCH FOUNDATION
Reel/Frame 024304/0527 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 8, 2010
From: KAPLAN, JERRY; WARD, DIANE M.; DE DOMENICO, IVANA
To: UTAH, UNIVERSITY OF
Reel/Frame 024228/0541 →
Continuity (2)
Provisional Application 61000584 · Oct 26, 2007
Related Publication 20100292147A1 · Nov 18, 2010